VIA Electronic Delivery Martin Huber, M.D. Dear Marty:Mersana Therapeutics, Inc. • November 7th, 2023 • Pharmaceutical preparations • Massachusetts
Company FiledNovember 7th, 2023 Industry Jurisdiction
VIA ELECTRONIC MAIL September 6, 2023 Arvin Yang Dear Arvin:Mersana Therapeutics, Inc. • November 7th, 2023 • Pharmaceutical preparations • Massachusetts
Company FiledNovember 7th, 2023 Industry JurisdictionAs we discussed, your employment with Mersana Therapeutics, Inc. (the “Company”) will end effective September 29, 2023 (the “Separation Date”). As we also discussed, the Company will provide you with the severance benefits described in paragraph 1 below if you sign and return this letter agreement to me on, but not before, the Separation Date and do not revoke your agreement (as described below).
AMENDMENT NO. 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • November 7th, 2023 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 7th, 2023 Company Industry JurisdictionThis Amendment No. 2 to Research Collaboration and License Agreement (this “Amendment”) is entered into and effective as of September 25, 2023 (the “Amendment Effective Date”) by and between Mersana Therapeutics, Inc., a Delaware corporation having its principal place of business at 840 Memorial Drive, Cambridge, MA 02139 (“Mersana”), and Janssen Biotech, Inc., a Pennsylvania corporation having its principal place of business at 800 Ridgeview Drive, Horsham, PA 19044 (“Janssen”). Mersana and Janssen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RETIREMENT AND SEPARATION AGREEMENTRetirement and Separation Agreement • November 7th, 2023 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 7th, 2023 Company Industry JurisdictionThis Retirement and Separation Agreement (the “Agreement”) is made as of September 5, 2023 (the “Agreement Effective Date”) by and between Anna Protopapas (the “Executive”) and Mersana Therapeutics, Inc. (“Mersana” or the “Company”) (together, the “Parties”).
AMENDMENT NO. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between MERSANA THERAPEUTICS, INC. and JANSSEN BIOTECH, INC. (effective February 2, 2022)Collaboration and License Agreement • November 7th, 2023 • Mersana Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 7th, 2023 Company IndustryTHIS AMENDMENT NO. 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Amendment No. 1”) is made and entered into as of July 12, 2023 (the “Amendment Effective Date”), by and between: